Real-World Outcomes in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) With Prior Proteasome Inhibitor and Lenalidomide Exposure in Sweden

被引：0
|
作者：
Luong, Vincent [1 ,2 ]
Kashif, Muhammad [1 ]
Uttervall, Katarina [1 ,2 ]
Bohlin, Anna [1 ]
Fernstrom, Annette Oster [1 ]
Qu, Ying [3 ]
Lee, Seina [4 ]
Mendes, Joao [5 ]
Van Hoorenbeeck, Sandra [6 ]
Franck, Eva Hellqvist [3 ]
He, Jianming [7 ]
Alici, Evren [1 ,2 ]
Lund, Johan [1 ,2 ]
机构：
[1] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Solna, Sweden
[2] Karolinska Univ Hosp, Dept Hematol, Solna, Sweden
[3] Janssen Cilag AB, Stockholm, Sweden
[4] Janssen Res & Dev, Raritan, NJ USA
[5] Janssen Cilag Farmaceut, Sao Paulo, Brazil
[6] Janssen Cilag NV, Beerse, Belgium
[7] Janssen Global Serv LLC, Raritan, NJ USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-407
引用
收藏
页码：S269 / S270
页数：2
相关论文
共 50 条
  • [1] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [2] Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Moon, Joon-Ho
    Ng, Soo Chin
    Park, Sung Soo
    Koh, Youngil
    Lee, Ji Hyun
    Eom, Hyeon-Seok
    Shin, Ho-Jin
    Lee, Je-Jung
    Do, Young Rok
    Wilfred, Gilbert
    Husin, Azlan
    Kim, Hyo Jung
    Wahid, S. Fadilah Abdul
    Lee, Myung-Won
    Heo, Hye-won
    Kim, Kihyun
    Chuncharunee, Suporn
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S263 - S264
  • [3] Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew
    Sperling, Adam
    Anderson, Larry
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S258 - S259
  • [4] Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)
    Sanchez, Larysa
    Cherepanov, Dasha
    Romanus, Dorothy
    Raju, Aditya
    Blazer, Marlo
    Farrelly, Eileen
    Stull, Dawn Marie
    Ailawadhi, Sikander
    BLOOD, 2020, 136
  • [5] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2023, 142
  • [6] Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Zhang, Shijia
    Richter, Joshua R.
    Kuo, Yen-Hong
    Schmidt, Linda
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Pierre, Amy
    Kumka, Susan
    Cuccurullo, Carmela
    Siegel, David S.
    BLOOD, 2016, 128 (22)
  • [7] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    HAEMATOLOGICA, 2016, 101 : 538 - 539
  • [8] Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma
    Mark, Tomer
    Falkenstein, Angelica
    Kish, Jonathan
    FUTURE ONCOLOGY, 2022, 18 (05) : 553 - 564
  • [9] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [10] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Shaikh, Hira
    Lochner, Jonathan
    Friend, Reed
    Snyder, Jordan
    Davis, James
    Patrus, Gina
    Dileo, Rachel
    Ahmed, Nausheen
    Mewawalla, Prerna
    Poonsombudlert, Kittika
    Struble, Emily
    Wolcott, Allyson
    Green, Kimberly
    Sparrow, Samantha
    Mushtaq, Muhammad Umair
    Paul, Barry
    Abdallah, Al-Ola
    Strouse, Christopher
    Hashmi, Hamza
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88
12345